Blockade of the renin-angiotensin system for renal future perspectives protection: from history to future perspective

Kobori H. , Nangaku M. , Navar LG , Nishiyama A. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 2007;59:251-87.

Hostetter TH , Rennke H. , Brenner BM The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies . Am J Med 1982;72:375-80.

Brunner HR , Kirsman DJ , Sealey JE , Laragh JH Hypertension of renal origin: evidence for two different mechanisms . Science 1971;174:1344-6.

Gavras H. , Brunner HR , Vaughan ED Jr , Laragh JH Angiotensin-sodium interaction in blood pressure maintenance of renal hypertensive and normotensive rats. Science 1973;180:1369-72.

Brunner HR , Gavras H. , Laragh JH , Keenan R. Ang II blockade in man by Sar1-Ala8-angiotensin II for understanding and treatment of high blood pressure. Lancet 1973;2:1045-8.

Gavras H. , Ribeiro AB , Gavras I. , Brunner HR Reciprocal relation between renin dependency and sodium dependency in essential hypertension. N Engl J Med 1976 ;295:1278-83.

Ferguson RK , Turini GA , Brunner HR , Gavras H. , McKinstry D. A specific orally active inhibitor of angiotensin-converting enzyme in man . Lancet 1977;1:775-8.

Brunner HR , Waeber B. , Wauters JP et al. Inappropriate renin secretion in hypertension of chronic renal failure unmasked by captopril (SQ 14,225). Lancet 1978;2:704-07.

Lazarus JM , Hampers CL , Bennett AH et al. Urgent bilateral nephrectomy for severe hypertension. Ann Intern Med 1972;76:733.

Hollenberg NK , Williams GH , Taub KJ et al. Renal vascular response to interruption of the renin-angiotensin system in normal man. Kidney Int 1977;12:285-93.

Burnier M. , Rutschmann B. , Nussberger J. et al. Salt-dependent renal effects of angiotensin II antagonist in healthy subjects. Hypertension 1993;22:339-47.

Gansevoort RT , deZeeuw D. , De Jong PE Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin angiotensin system? Kidney Int 1994;45:861-7.

Anderson S. , Rennke HG , Brenner BM Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986 ;77:1993-2000.

Zatz R. , Rentz Dunn B. , Meyer TW et al. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986;77:1925-30.

Taguma Y. , Kitamoto Y. , Futaki G. et al. Effect of captopril on heavy proteinuria in azometic diabetics . N Eng J Med 1985;313:1617-20.

Ravid M. , Lang R. , Rachmani R. , Lishner M. Long-term renal protective effect of angiotensin converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Arch Int Med 1996;156:286-9.

Gansevoort RT , Sluiter WA , Hemmelder MH et al. Antiproteinuric effect of blood pressure lowering agents: a meta-analysis of comparative trials . Nephrol Dial Transplant 1995;10:1963-74.

Lewis EJ , Hunsicker LG , Bain RP , Rohde RD The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456-62.

Holman R. , Turner R. , Stratton I. et al. for the UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39 . BMJ 1998;317:713-20.

Maschio G. , Alberti D. , Janin G. et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 1996;334:939-45.

Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001;103:904-12.

Brenner BM , Cooper ME , de Zeeuw D. et al. RENAAL Study Investigators. Effects of losartan on renal and cardio-vascular outcomes in patients with type 2 diabetes and nephropathy . N Engl J Med 2001;345:861-9.

Lewis EJ , Hunsicker, LG , Clarke WR et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.

Parving HH , Lehnert H. , Brochner-Mortensen J. et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.

Viberti G. , Wheeldon NM MicroAlbuminuria Reduction With VALsartan (MARVAL) study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002 ;106:672-8.

Mogensen CE , Neldam S. , Tikkanen I. et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000;321:1440-4.

Burgess E. , Bakris G. , Weir M. , Koval S. Comparative long term effects of two AT1 receptor blockers on proteinuria in patients with type 2 diabetes and overt nephropathy and hypertension: results of the AMADEO trial. J Hypertens 2007;25:S276.

Barnett AH , Bain SC , Bouter P. , Karlberg B. , Madsbad S. , Jervell J. , Mustonen J. Angiotensin-receptor blockade versus converting enzyme inhibition in type 2 diabetes and nephropathy. N Eng J Med 2004 ;351:1952-61.

Ruggenenti P. , Fassi A. , Ilieva AP et al. Preventing microalbuminuria in type 2 diabetes. N Eng J Med 2004;351:1941-51.

Mancia G. , De Backer G. , Dominiczak A. et al. 2007 Guidelines for the management of arterial hypertension. J Hypertens 2007;25:1105-87.

Azizi M. , Chatellier G. , Guyene TT , Murieta-Geoffroy D. , Ménard J. Additive effects of combined angiotensinconverting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodiumdepleted normotensives . Circulation 1995;92:825-34.

Nakao N. , Yoshimura A. , Morita H. et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003 ;361:117-24.

Kunz R. , Friedrich C. , Wolbers M. , Mann J FE Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease . Ann Intern Med 2007, epub ahead of print.

Parving HE , Lewis JB , Lewis EJ , Hollenberg NK Aliskiren in the evaluation of proteinuria in diabetes (AVOID). JASN SA-PO1051, 2007. (Abstract)

Mazzolai L. , Maillard M. , Rossat J. , Nussberger J. , Brunner HR , Burnier M. Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists. Hypertension 1999;33:850-5.

Forclaz A. , Maillard M. , Nussberger J. , Brunner HR , Burnier M. Angiotensin II receptor blockade: is there truly a benefit of adding an ACE inhibitor? Hypertension 2003;41:31-6.

Rossing K. , Schjoedt KJ , Jensen BR , Boomsma , Parving HH Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int 2005;68:1190-8.

Schmieder RE , Klingbeil AU , Fleischmann EH , Veelken R. , Delles C. Additional antiproteinuric effect of ultrahigh dose of candesartan: a double-blind, randomized prospective study. JASN 2005;16:3038-45.

Hollenberg NK , Parving HH , Viberti G. et al. Albuminuria response to very high dose of valsartan in type 2 diabetes mellitus. J Hypertens 2007;25:1921-6.

Burgess ED , Muirhead N. , De Cotret PR A Double-Blind Randomized Controlled Trial of High Dose Candesartan Cilexetil in Proteinuric Renal Disease - Results from SMART (Supra Maximal Atacand Renal Trial). JASN SA-FC104, 2007 . (Abstract)

Bakris GL , Ruilope L. , Locatelli F. et al. Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. Kidney Int 2007;72:879-85.